INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

• US 20120122931A1
• Filed: 07/26/2010
• Published: 05/17/2012
• Est. Priority Date: 07/27/2009
• Status: Abandoned Application

• Current Assignee: Kissei Pharmaceutical Company Limited
• Original Assignee: Kissei Pharmaceutical Company Limited
• Inventors: Kondo, Tatsuhiro, Kondo, Atsushi, Tatani, Kazuya, Kawamura, Naohiro
• Application Number:
  US13/387,291
• Publication Number:
  US 20120122931A1
• Time in Patent Office: Days
• US Class Current: 514/333
• CPC Class Codes: A61K 31/404 Indoles, e.g. pindolol
• CPC Class Codes: A61K 31/422 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 209/18 Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• CPC Class Codes: C07D 401/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 401/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 405/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 409/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 409/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 409/14 containing three or more hetero rings
• CPC Class Codes: C07D 413/14 containing three or more hetero rings
• CPC Class Codes: C07D 417/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 417/14 containing three or more hetero rings

Abstract

A compound represented by the general formula (I) of the present invention, which has an EP₁ receptor antagonism:

• • [wherein A represents a benzene ring or the like; Y represents a C_1-6 alkylene group or the like; R^N represents a hydrogen atom or a C_1-6 alkyl group; R¹ represents a hydrogen atom, a C_1-6 alkyl group or the like; R² represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic group which may have a substituent, a 6-membered aromatic heterocyclic group which may have a substituent or the like; R³ represents a halogen atom, a C_1-6 alkoxy group or the like; R⁴ represents a hydrogen atom or the like; and R⁵ represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

Claims

1. A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof:

2. The compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein A is a group selected from the group consisting of the following a) to d):

3. The compound as claimed in claim 2 or a pharmaceutically acceptable salt thereof, wherein A is a group selected from the group consisting of the following a) to c):

4. The compound as claimed in claim 3 or a pharmaceutically acceptable salt thereof, wherein R² is a group selected from the group consisting of the following a) to c):

a) a branched C_3-6 alkyl group,

b) a phenyl group, and

c) a 5-membered aromatic heterocyclic group or a 6-membered aromatic heterocyclic group;

R³ is a halogen atom, a C_1-6 alkyl group, a halo-C_1-6 alkyl group, a C_1-6 alkoxy group, a halo-C_1-6 alkoxy group, or a cyano group;

R⁴ is a hydrogen atom; and

R⁵ is a hydrogen atom.

5. The compound as claimed in claim 4 or a pharmaceutically acceptable salt thereof, wherein R¹ is a hydrogen atom.

6. The compound as claimed in claim 5 or a pharmaceutically acceptable salt thereof, wherein Y is a methylene group and R^N is a hydrogen atom.

7. The compound as claimed in claim 6 or a pharmaceutically acceptable salt thereof, wherein R² is a phenyl group, a 5-membered aromatic heterocyclic group, or a 6-membered aromatic heterocycle.

8. The compound as claimed in claim 7 or a pharmaceutically acceptable salt thereof, wherein R³ is a halogen atom or a C_1-6 alkoxy group.

9. The compound as claimed in claim 6 or a pharmaceutically acceptable salt thereof, wherein R² is an isopropyl group, an isobutyl group, a sec-butyl group, or a tert-butyl group.

10. The compound as claimed in claim 9 or a pharmaceutically acceptable salt thereof, wherein R³ is a halogen atom or a C_1-6 alkoxy group.

11. The compound as claimed in claim 2 or a pharmaceutically acceptable salt thereof, wherein A is a group represented by the following formula:

12. The compound as claimed in claim 11 or a pharmaceutically acceptable salt thereof, wherein R¹ is a hydrogen atom.

13. The compound as claimed in claim 3 or a pharmaceutically acceptable salt thereof, wherein R² is a group selected from the group consisting of the following a) to d):

14. The compound as claimed in claim 13 or a pharmaceutically acceptable salt thereof, wherein R¹ is a hydrogen atom.

15. A pharmaceutical composition comprising the compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

18. A method for preventing or treating lower urinary tract symptoms, comprising administering an effective amount of the compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

16-17. -17. (canceled)